These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 33164519)
1. Initial Leuprolide Acetate Release from Poly(d,l-lactide- Li Z; Mu H; Larsen SW; Jensen H; Østergaard J Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519 [TBL] [Abstract][Full Text] [Related]
2. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging. Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591 [TBL] [Abstract][Full Text] [Related]
3. An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants. Li Z; Mu H; Weng Larsen S; Jensen H; Østergaard J Int J Pharm; 2021 Nov; 609():121183. PubMed ID: 34653562 [TBL] [Abstract][Full Text] [Related]
4. Implant dynamics, inner structure, and their impact on drug release of in situ forming implants uncovered through CT imaging. Lin X; Al Zouabi NN; Ward LE; Zhen Z; Darji M; Masese FK; Hargrove D; O'Reilly Beringhs A; Kasi RM; Li Q; Zhang Q; Qin B; Wang Y; Jay M; Yuan H; Lu X J Control Release; 2024 Nov; 375():802-811. PubMed ID: 39349184 [TBL] [Abstract][Full Text] [Related]
5. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. Luan X; Bodmeier R J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851 [TBL] [Abstract][Full Text] [Related]
6. Effect of implant formation on drug release kinetics of in situ forming implants. Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755 [TBL] [Abstract][Full Text] [Related]
7. In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. Mashayekhi R; Mobedi H; Najafi J; Enayati M Daru; 2013 Jul; 21(1):57. PubMed ID: 23856431 [TBL] [Abstract][Full Text] [Related]
8. Phase separation of in situ forming poly (lactide-co-glycolide acid) implants investigated using a hydrogel-based subcutaneous tissue surrogate and UV-vis imaging. Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J J Pharm Biomed Anal; 2017 Oct; 145():682-691. PubMed ID: 28803207 [TBL] [Abstract][Full Text] [Related]
9. Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery. Thalhauser S; Peterhoff D; Wagner R; Breunig M Eur J Pharm Biopharm; 2020 Nov; 156():1-10. PubMed ID: 32860903 [TBL] [Abstract][Full Text] [Related]
10. In-situ forming PLGA implants: Towards less toxic solvents. Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617 [TBL] [Abstract][Full Text] [Related]
11. In situ-forming PLGA implants loaded with leuprolide acetate/β-cyclodextrin complexes: mathematical modelling and degradation. Rahimi M; Mobedi H; Behnamghader A J Microencapsul; 2016 Jun; 33(4):355-64. PubMed ID: 27530523 [TBL] [Abstract][Full Text] [Related]
12. Leuprolide Acetate Release Study from γ-Irradiated PLGA-based In Situ Forming System. Shapourgan M; Mobedi H; Sheikh N; Behnamghader A; Mashak A Curr Drug Deliv; 2017; 14(8):1170-1177. PubMed ID: 28530536 [TBL] [Abstract][Full Text] [Related]
13. In-situ forming implants for the treatment of periodontal diseases: Simultaneous controlled release of an antiseptic and an anti-inflammatory drug. Lizambard M; Menu T; Fossart M; Bassand C; Agossa K; Huck O; Neut C; Siepmann F Int J Pharm; 2019 Dec; 572():118833. PubMed ID: 31715363 [TBL] [Abstract][Full Text] [Related]
14. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Luan X; Bodmeier R Eur J Pharm Sci; 2006 Feb; 27(2-3):143-9. PubMed ID: 16243496 [TBL] [Abstract][Full Text] [Related]
16. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Kranz H; Bodmeier R Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569 [TBL] [Abstract][Full Text] [Related]
17. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. Dong WY; Körber M; López Esguerra V; Bodmeier R J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145 [TBL] [Abstract][Full Text] [Related]
18. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947 [TBL] [Abstract][Full Text] [Related]
19. Noninvasive characterization of in situ forming implants using diagnostic ultrasound. Solorio L; Babin BM; Patel RB; Mach J; Azar N; Exner AA J Control Release; 2010 Apr; 143(2):183-90. PubMed ID: 20060859 [TBL] [Abstract][Full Text] [Related]
20. Coloring of PLGA implants to better understand the underlying drug release mechanisms. Bode C; Kranz H; Siepmann F; Siepmann J Int J Pharm; 2019 Oct; 569():118563. PubMed ID: 31351179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]